Welcome Healthy Eyes Advantage Members!
MacuLogix is excited to partner with you to adapt, evolve, and grow your approach to age-related macular degeneration. Together, we can eliminate blindness caused by AMD.
Join the AMD Revolution
Practical Opportunities in AMD Management
2020 has been a year of change – for the world, for eye care, and for the treatment and management of AMD.
Whether you have a strong AMD program, need to up your game, or are thinking about creating one, our latest e-book, Practical Opportunities in AMD Management can provide you with updated information for how to improve patient outcomes and enhance practice revenue.
This 16-page e-book features industry experts who share their knowledge and experience in diagnosing and managing AMD. It also includes short vignettes from various optometrists that provide real-world examples of how they’ve implemented dark adaptation testing, as well as advice for their colleagues.
$0 Payments for 6 Months
No payments for 6 months* will help you take on AMD – one of eye care’s biggest opportunities to impact patients’ lives and practice revenue. You can focus on your patients and their medical needs while boosting revenue and building cash reserves – with no up-front investment.
For more information or to order your AdaptDx ProTM, contact Leah.
Director of Strategic Accounts
*Offers applies to a 42-month premium subscription plan when you purchase in 2020. Ask your Regional Sales Executive for full details. This offer is valid for eye care professionals in the US only.
Dr. Jordan's Success Story
The changing landscape of eye care has led many providers to transition their focus from refractive to a more medically focused practice model in order to drive revenue.
Dr. Jordan of Rinkov Eye Centers in Westerville, OH, began utilizing AdaptDx technology in 2019 and was able to increase revenue in his practice by $196,177 in just 8 months.
Tour our Virtual Exhibit
Our interactive Virtual Exhibit allows you to meet the newest member of our team – TheiaTM, the on-board technician for the AdaptDx Pro headset dark adaptometer. Theia will welcome you to the booth as you learn how tackling AMD can benefit your practice.
Explore the exhibit at your leisure – without any sales pressure – and see this amazing technology for yourself. When you are ready to learn more, just enter your ZIP Code into the laptop in the booth to find your Regional Sales Executive.
Find Your Way Forward
Early detection and treatment of AMD can help you combat the leading cause of adult blindness in the US while doing the right thing for your patients and your practice. Here’s how:
1. Put Patient Care First
This year’s events may have forced you to take a break from caring for your patients – but eye disease has not taken that same break. Accept the challenge to tackle AMD, one of eye care’s biggest opportunities to impact patients’ lives.
2. Create Efficiency & Focus on Hygiene
The AdaptDx Pro is guided by Theia, an onboard technician who increases consistency in each patient’s testing experience, freeing up your techs to attend to other tasks. Our single-use Comfort Guard™ eyecup covers provide a comfortable, sanitary test experience for each patient.
3. Drive Medical Revenue
Patient discretionary spending may be reduced, even for months – making medical revenue more vital than ever. Dark adaptation testing is a reimbursable service, using CPT 92284, that can dramatically increase revenue for your practice.
4. Create Revenue from Current Patients
The AdaptDx Pro leverages patients already in the practice, allowing you to generate revenue as quickly and easy as possible, without the need to market and acquire a new audience.
5. Increase Cash Reserves
Eye care professionals are dealing with reduced cash flow, making it difficult to invest in new technology. Our new subscription model allows you to start earning revenue with no up-front investment.
Impaired Dark Adaptation: The Earliest Biomarker of AMD (video)
Before drusen are visible, an invisible layer of cholesterol builds up between the pigmented layer of the retina (RPE) and the elastic layer of Bruch’s membrane. These cholesterol deposits — basal laminar (BLamD) and basal linear (BLinD) — cause oxidative stress and inflammation, hindering nutrient transportation to photoreceptor cells. As photoreceptor cells die, it becomes harder for the eyes to adjust to the darkness, and night vision declines. This dark adaptation impairment is the first sign of age-related macular degeneration (AMD).
The cholesterol deposits grow over time. Where they become sufficiently thickened, the lesion becomes clinically detectable as a druse. The first visible druse caused by AMD is just the tip of the iceberg of these lesions.
Research has shown that impaired dark adaptation function can be detected at least three years before drusen are clinically evident, allowing for earlier diagnosis, treatment, and monitoring of AMD.